BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28539837)

  • 1. Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
    Wang Y; Hou N; Cheng X; Zhang J; Tan X; Zhang C; Tang Y; Teng Y; Yang X
    Int J Biol Sci; 2017; 13(5):652-659. PubMed ID: 28539837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
    Riquelme E; Behrens C; Lin HY; Simon G; Papadimitrakopoulou V; Izzo J; Moran C; Kalhor N; Lee JJ; Minna JD; Wistuba II
    Cancer Res; 2016 Feb; 76(3):675-85. PubMed ID: 26676756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
    Zhang H; Fillmore Brainson C; Koyama S; Redig AJ; Chen T; Li S; Gupta M; Garcia-de-Alba C; Paschini M; Herter-Sprie GS; Lu G; Zhang X; Marsh BP; Tuminello SJ; Xu C; Chen Z; Wang X; Akbay EA; Zheng M; Palakurthi S; Sholl LM; Rustgi AK; Kwiatkowski DJ; Diehl JA; Bass AJ; Sharpless NE; Dranoff G; Hammerman PS; Ji H; Bardeesy N; Saur D; Watanabe H; Kim CF; Wong KK
    Nat Commun; 2017 Apr; 8():14922. PubMed ID: 28387316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.
    Serresi M; Siteur B; Hulsman D; Company C; Schmitt MJ; Lieftink C; Morris B; Cesaroni M; Proost N; Beijersbergen RL; van Lohuizen M; Gargiulo G
    J Exp Med; 2018 Dec; 215(12):3115-3135. PubMed ID: 30487290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.
    Serresi M; Gargiulo G; Proost N; Siteur B; Cesaroni M; Koppens M; Xie H; Sutherland KD; Hulsman D; Citterio E; Orkin S; Berns A; van Lohuizen M
    Cancer Cell; 2016 Jan; 29(1):17-31. PubMed ID: 26766588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
    Chen F; Byrd AL; Liu J; Flight RM; DuCote TJ; Naughton KJ; Song X; Edgin AR; Lukyanchuk A; Dixon DT; Gosser CM; Esoe DP; Jayswal RD; Orkin SH; Moseley HNB; Wang C; Brainson CF
    Nat Commun; 2023 Jan; 14(1):336. PubMed ID: 36670102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Fujimoto J; Nunomura-Nakamura S; Liu Y; Lang W; McDowell T; Jakubek Y; Ezzeddine D; Kapere Ochieng J; Petersen J; Davies G; Fukuoka J; Wistuba II; Ehli E; Fowler J; Scheet P; Kadara H
    Int J Cancer; 2017 Oct; 141(8):1589-1599. PubMed ID: 28653505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression.
    Wan J; Zhan J; Li S; Ma J; Xu W; Liu C; Xue X; Xie Y; Fang W; Chin YE; Zhang H
    Nucleic Acids Res; 2015 Apr; 43(7):3591-604. PubMed ID: 25800736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways.
    Song NY; Zhu F; Wang Z; Willette-Brown J; Xi S; Sun Z; Su L; Wu X; Ma B; Nussinov R; Xia X; Schrump DS; Johnson PF; Karin M; Hu Y
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E812-E821. PubMed ID: 29311298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
    Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
    Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
    Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
    Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
    Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
    Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
    Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Is Required for Uterine Epithelial Integrity.
    Fang X; Ni N; Lydon JP; Ivanov I; Bayless KJ; Rijnkels M; Li Q
    Am J Pathol; 2019 Jun; 189(6):1212-1225. PubMed ID: 30954472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.